Mass spectrometry-based protein assays for in vitro diagnostic testing

Expert Review of Molecular Diagnostics

Volumn 12, Issue 3, 2012, Pages 235-239

  Nedelkov, Dobrin ^a,b  

^a Intrinsic Bioprobes Incorporated   (United States)

^b Institute for Population Proteomics   (United States)

Author keywords

biomarker; FDA; immunoassay; IVD; mass spectrometry; protein

Indexed keywords

CYSTATIN C;

DIAGNOSTIC TEST; IMMUNOASSAY; IN VITRO STUDY; MASS SPECTROMETRY; PROTEIN DETERMINATION; REVIEW; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CYSTATINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOASSAY; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859384372     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.15     Document Type: Review

References (33)

1. Kuzyk MA, Smith D, Yang J et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell Proteomics 8(8), 1860-1877 (2009).
2. Whiteaker JR, Zhao L, Abbatiello SE et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell Proteomics 10(4), M110 005645 (2011).
3. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell Proteomics 9(1), 184-196 (2010).
4. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem. 56(12), 1804-1813 (2010).
5. Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D. Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS One 6(3), e17282 (2011).
6. Kumar V, Barnidge DR, Chen LS et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 56(2), 306-313 (2010).
7. Lopez MF, Rezai T, Sarracino DA et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 56(2), 281-290 (2010).
8. Trenchevska O, Kamcheva E, Nedelkov D. Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J. Proteome Res. 9(11), 5969-5973 (2010).
9. Trenchevska O, Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 9(1), 19 (2011).
10. Saudek CD, Brick JC. The clinical use of hemoglobin A1c. J. Diabetes Sci. Technol. 3(4), 629-634 (2009).
11. Nedelkov D. Mass spectrometry-based immunoassays for the next phase of clinical applications. Expert. Rev. Proteomics 3(6), 631-640 (2006).
12. Nelson RW, Krone JR, Bieber AL, Williams P. Mass-spectrometric immunoassay. Anal. Chem. 67(7), 1153-1158 (1995).
13. Niederkofler EE, Kiernan UA, O'Rear J et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 1(4), 258-264 (2008).
14. Nedelkov D. Population proteomics: addressing protein diversity in humans. Expert Rev. Proteomics 2(3), 315-324 (2005).
15. Grubb AO. Cystatin C - properties and use as diagnostic marker. Adv. Clin. Chem. 35, 63-99 (2000).
16. Henskens YM, Veerman EC, Nieuw Amerongen AV. Cystatins in health and disease. Biol. Chem. Hoppe Seyler 377(2), 71-86 (1996).
17. Reed CH. Diagnostic applications of Cystatin C. Br. J. Biomed. Sci. 57(4), 323-329 (2000).
18. Randers E, Erlandsen EJ. Serum Cystatin C as an endogenous marker of the renal function - a review. Clin. Chem. Lab. Med. 37(4), 389-395 (1999).
19. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum Cystatin C as a marker of the renal function. Scand. J. Clin. Lab. Invest. 58(7), 585-592 (1998).
20. Dharnidharka VR, Kwon C, Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 40(2), 221-226 (2002).
21. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin. Chem. 48(5), 699-707 (2002).
22. Li J, Dunn W, Breaud A, Elliott D, Sokoll LJ, Clarke W. Analytical performance of 4 automated assays for measurement of Cystatin C. Clin. Chem. 56(8), 1336-1339 (2010).
23. Trenchevska O, Kamcheva E, Nedelkov D. Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 11(18), 3633-3641 (2011).
24. Erlandsen EJ, Randers E, Kristensen JH. Reference intervals for serum Cystatin C and serum creatinine in adults. Clin. Chem. Lab. Med. 36(6), 393-397 (1998).
25. Asgeirsson B, Haebel S, Thorsteinsson L et al. Hereditary Cystatin C amyloid angiopathy: monitoring the presence of the Leu-68->Gln Cystatin C variant in cerebrospinal fluids and monocyte cultures by MS. Biochem. J. 329(Pt 3), 497-503 (1998).
26. Grubb A, Lofberg H. Human g-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc. Natl Acad. Sci. USA 79(9), 3024-3027 (1982).
27. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol. Cell Proteomics 6(7), 1183-1187 (2007).
28. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3(2), 235-244 (2004).
29. Kim K, Kim Y. Preparing multiple-reaction monitoring for quantitative clinical proteomics. Expert Rev. Proteomics 6(3), 225-229 (2009).
30. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877(13), 1229-1239 (2009).
31. Yocum AK, Chinnaiyan AM. Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct. Genomic. Proteomic. 8(2), 145-157 (2009).
32. Cho WC. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome. Expert Rev. Proteomics 8(1), 1-4 (2011).
33. Li J, Kelm KB, Tezak Z. Regulatory perspective on translating proteomic biomarkers to clinical diagnostics. J. Proteomics 74(12), 2682-2690 (2011).